Screening methods for the identification of anti-HIV compounds employing a cyclosporine-specific monoclonal antibody that cross-reacts with HIV-1 p24
AssigneeThe Trustees of Columbia University in the City of New York
InventorsBernard F. Erlanger, Bi-Xing Chen
Life of this patent
Estimating the term…
Abstract
The subject invention provides new uses for novel derivatives of cyclosporine A and antibodies directed thereto. Specifically, the derivatives and antibodies are useful in methods of treating AIDS, methods of purifying the Gag protein of HIV, methods of screening for anti-HIV compounds, and methods for detecting HIV in a subject. The derivatives and antibodies can also be incorporated into a kit useful for screening for anti-HIV compounds.
Claims6
A method of testing whether a composition of matter inhibits binding between an HIV-1 p24 gag protein and a detectably labeled cyclosporine-specific antibody which cross reacts with HIV-1 p24 gag protein which comprises:
- a) immobilizing the composition of matter, wherein the composition of matter has the structure:
- wherein a plurality of R's are X and the remainder are H, wherein X is a ligand comprising a reactive group and wherein X is bonded to the composition of matter by a photochemical reaction between a hydrogen of cyclosporine A and a photochemically activatable precursor of X;
- b) contacting the immobilized composition of matter from (a) with a mixture of HIV-1 p24 gag protein and a detectably labeled antibody which specifically binds to N-methyl leucine residues 9 and 10 of cyclosporine and cross reacts with HIV-1 p24 gag protein under conditions allowing for the labelled antibody to bind to the immobilized composition of matter from (a) and form a complex therewith;
- c) separating any unbound labeled antibody from any complex formed in (b);
- d) detecting any labeled antibody bound to the complex in (b);
- and
- e) quantitating the amount of labeled antibody from (d), a decrease in the amount of antibody bound to the composition of matter after incubation with the HIV-1 p24 gag protein in step (b) compared to the amount of antibody bound to the composition of matter in the absence of HIV-1 p24 gag protein indicating that the composition of matter inhibits binding between the HIV-1 p24 gag protein and the detectably labeled antibody.
A kit for testing whether a composition of matter inhibits binding between HIV-1 p24 gag protein and a detectably labeled cyclosporine-specific antibody which cross reacts with HIV-1 p24 gag protein which comprises:
- a) a plate comprising a plurality of wells;
- b) the composition of matter immobilized upon the wells, wherein the composition of matter has the structure:
- wherein a plurality of R's are X and the remainder are H, wherein X is a ligand comprising a reactive group and wherein X is bonded to the composition of matter by a photochemical reaction between a hydrogen of cyclosporine A and a photochemically activatable precursor of X;
- and
- c) a solution comprising the detectably labeled cyclosporine-specific antibody which cross reacts with HIV-1 p24 gag protein and which specifically binds to N-methyl leucine residues 9 and 10 of cyclosporine;
- and
- d) a solution comprising the HIV-1 p24 gag protein.
Dependencies are inferred from the claim text.